Preclinical Pharmacology Platform

About Predictive Biology

Predictive Biology is a private, pre-clinical stage biotech firm developing a proprietary in vitro genetics platform for target discovery and preclinical pharmacology. Its core asset is a large, genetically diverse panel of over 1,000 mouse embryonic stem cell lines derived from Diversity Outbred mice, which it differentiates into various cell types and organoids for high-throughput phenotypic and molecular QTL mapping. The company operates primarily as a platform and services partner for pharmaceutical and biotech companies, focusing on neuroscience, toxicology, and drug mechanism evaluation, and is currently pre-revenue with SBIR grant funding supporting some programs.

Therapeutic Areas